Skip to main content

Advertisement

Table 1 Clinical status and profile of the patients

From: Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

  KIF20A peptide vaccine treatment Best supportive care
  Chiba (n = 31) * Chiba (n = 9) * Multi-center (n = 81) **
Age (average, (range)) 61.3 (33–80) 64 (53–82) 64.5 (41–85)
Sex (Male: Female) 17:14 5:4 49:32
Performance status (0:1:2:3) 11:8:12:0 1:3:3:2 13:28:36:0 ***
Status of primary lesion (Resected: Unresected) 15:16 1:8 23:58
Median survival time (days) 142.0 ± 23.7 83.0 ± 33.5 62.0 ± 6.5
Mean survival time (days) 171.8 ± 23.8 93.3 ± 14.8 91.1 ± 11.6
  1. *, Clinical data obtained at our institution, Chiba Tokushukai Hospital.
  2. **, Clinical data of Multi-center (n = 81) include those obtained from Chiba and other three hospitals.
  3. ***, 4 cases were excluded, since Performance Status was not determined.